Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Accounts Payables: 2009-2025

Historic Accounts Payables for Rockwell Medical (RMTI) over the last 17 years, with Sep 2025 value amounting to $1.5 million.

  • Rockwell Medical's Accounts Payables fell 41.58% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 41.58%. This contributed to the annual value of $2.9 million for FY2024, which is 36.47% down from last year.
  • Per Rockwell Medical's latest filing, its Accounts Payables stood at $1.5 million for Q3 2025, which was up 1.40% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Rockwell Medical's Accounts Payables peaked at $5.9 million during Q2 2023, and registered a low of $1.5 million during Q2 2025.
  • Its 3-year average for Accounts Payables is $3.5 million, with a median of $3.3 million in 2024.
  • As far as peak fluctuations go, Rockwell Medical's Accounts Payables surged by 101.46% in 2023, and later tumbled by 60.87% in 2025.
  • Over the past 5 years, Rockwell Medical's Accounts Payables (MRQ) stood at $3.7 million in 2021, then increased by 8.40% to $4.1 million in 2022, then rose by 11.42% to $4.5 million in 2023, then tumbled by 36.47% to $2.9 million in 2024, then crashed by 46.92% to $1.5 million in 2025.
  • Its Accounts Payables stands at $1.5 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.9 million for Q1 2025.